Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease

This study aims to evaluate the thera peutic alternatives that would allow for the appropriate management of patients with both SpA and IBD.Key Points• Collaboration between gastroenterologists and rheumatologists is recommended to improve the management of patients with spondyloarthritis (SpA) and inflammatory bowel disease (IBD).• When treating SpA occurring simultaneously with IBD, it would be appropriate to give priority to the active disease.• Considering its well-proven efficacy in both conditions, anti-tumor necrosis factor (TNF) therapy remains the corner stone in the treatment of these patients.• Other therapeutic options such as Janus kinases (JAK) inhibitors, interleukin (IL)-23 and IL-12 inhibitors, and vedolizumab are still under investigation.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research